Microglial cells: the main HIV-1 reservoir in the brain
C Wallet, M De Rovere, J Van Assche… - Frontiers in cellular …, 2019 - frontiersin.org
Despite efficient combination of the antiretroviral therapy (cART), which significantly
decreased mortality and morbidity of HIV-1 infection, a definitive HIV cure has not been …
decreased mortality and morbidity of HIV-1 infection, a definitive HIV cure has not been …
Targeting the latent reservoir for HIV-1
S Sengupta, RF Siliciano - Immunity, 2018 - cell.com
Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
Euphorbia diterpenoids: isolation, structure, bioactivity, biosynthesis, and synthesis (2013–2021)
Z Zhan, S Li, W Chu, S Yin - Natural Product Reports, 2022 - pubs.rsc.org
Covering: 2013 to 2021 As the characteristic metabolites of Euphorbia plants, Euphorbia
diterpenoids have always been a hot topic in related science communities due to their …
diterpenoids have always been a hot topic in related science communities due to their …
The current status of latency reversing agents for HIV-1 remission
A Rodari, G Darcis, CM Van Lint - Annual review of virology, 2021 - annualreviews.org
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1
(HIV-1) replication but is not curative because cART interruption almost invariably leads to a …
(HIV-1) replication but is not curative because cART interruption almost invariably leads to a …
Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs
One of the most explored therapeutic approaches aimed at eradicating HIV-1 reservoirs is
the “shock and kill” strategy which is based on HIV-1 reactivation in latently-infected cells …
the “shock and kill” strategy which is based on HIV-1 reactivation in latently-infected cells …
The role of macrophages in HIV-1 persistence and pathogenesis
Z Kruize, NA Kootstra - Frontiers in microbiology, 2019 - frontiersin.org
Current antiretroviral therapy (ART) effectively suppresses Human Immunodeficiency Virus
type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV …
type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV …
HIV “shock and kill” therapy: In need of revision
The implementation of antiretroviral therapy 23 years ago has rendered HIV infection
clinically manageable. However, the disease remains incurable, since it establishes latent …
clinically manageable. However, the disease remains incurable, since it establishes latent …
The reservoir of latent HIV
J Chen, T Zhou, Y Zhang, S Luo, H Chen… - Frontiers in cellular …, 2022 - frontiersin.org
The persistence of latent reservoir of the human immunodeficiency virus (HIV) is currently
the major challenge in curing HIV infection. After HIV infects the human body, the latent HIV …
the major challenge in curing HIV infection. After HIV infects the human body, the latent HIV …
Latency reversal and viral clearance to cure HIV-1
DM Margolis, JV Garcia, DJ Hazuda, BF Haynes - Science, 2016 - science.org
BACKGROUND A central challenge to emerging efforts to cure HIV infection is the
persistence of quiescent but replication-competent proviral genomes in resting CD4+ T …
persistence of quiescent but replication-competent proviral genomes in resting CD4+ T …
Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications
V Avettand-Fènoël, L Hocqueloux… - Clinical microbiology …, 2016 - Am Soc Microbiol
SUMMARY HIV-1 DNA persists in infected cells despite combined antiretroviral therapy
(cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs …
(cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs …